Astellas Pharma Inc.: U.S. FDA Approves Expanded Label for Astellas' IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy
IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...
Le Lézard22h
U.S. FDA Approves Expanded Label for Astellas' IZERVAYtm (avacincaptad pegol intravitreal solution) for Geographic Atrophy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAYtm ...
TMCnet9h
Two New Studies Demonstrate Proven Impact of Viz.ai's Stroke Solution on Patient Outcomes and Hospital Economics
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care. Two studies, presented at the ...
battlefordsnow23h
Local mom speaks out after daughter in wheelchair following misdiagnosis
Olivia had come into the hospital in a wheelchair and when they asked her to get out and stand up, she fell. After being ...